US4846782A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of cancer with interferon and radiotherapy
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1987-11-25
•
Granted: 1989-07-11
•
Expires: 2007-11-25
Abstract
Abstract Radiation sensitive human cancers are treated with combined interferon and radiation therapy.
Inventors
- 👤 Eric Bonnem
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:57
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
72 words
A method of treating radiation sensitive human cancers in patients in need of such treatment which comprises administering subcutaneously to such patients between 2.0×10 6 IU/m 2 and 5.0×10 6 IU/m 2 of recombinant DNA-alpha-2-interferon three days a week at a time on those days prior to radiation therapy wherein radiation doses of from 15 to 35 Gy are administered five days a week including those days on which interferon is administered.
Claim 2
Independent Claim
72 words
A method of treating radiation sensitive human cancers in patients in need of such treatment which comprises administering subcutaneously to such patients between 2.0×10 6 IU/m 2 and 5.0×10 6 IU/m 2 of recombinant DNA-alpha-2-interferon three days a week at a time on those days prior to radiation therapy wherein radiation doses of from 15 to 35 Gy are administered five days a week including those days on which interferon is administered.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-10 | 1993-01-09 | 1993-07-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-10 | 1997-01-09 | 1997-07-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-10 | 2001-01-09 | 2001-07-11 | $7700.00 | Window Closed / Lapsed |